Merrimack Pharma (MACK) is a cancer biotech with a diverse early-late stage clinical development pipeline that is summarized below.
CLINICAL TRIAL CATALYSTS (status updated in 7/12 SEC 424B5 prospectus filing related to recent offering):
1.) MM-398 (novel encapsulated liposomal formulation of approved anti-cancer drug irinotecan) is currently being evaluated in a Phase III (NAPOLI-1) clinical trial with expected completion of enrollment during Q3 2013 and top-line results expected during Q4 2013 to Q1 2014.
MM-398 is being evaluated for the treatment of metastatic pancreatic cancer that has progressed on gemcitabine treatment (i.e. a second-line treatment indication). ClinicalTrials.gov ID NCT01494506 is the identifier for the study and MM-398 has US and EU Orphan Drug status and...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: